Q-omics provides the consensus-scored RNF128 profile across patient tissues and cancer cell-line models. RNF128 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNF128 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, RNF128 RNA expression shows 16,748 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KICH, and TGCT as cancer lineages where RNF128 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF128 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF128 survival associations across molecular data types. RNF128 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF128 RNA expression–survival associations across cancer types. High RNF128 expression shows unfavorable associations in MESO, UVM, KIRP, UCEC, KICH and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RNF128 RNA expression.
This table summarizes RNF128 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RNF128. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF128 shows lower tumor expression in KICH, LUSC, LUAD and BRCA and higher tumor expression in KIRC and KIRP. The KICH box plot shows higher RNF128 RNA expression in normal versus tumor tissue (log2 FC = −4.893, t-test p < 0.001).
This table shows molecular features associated with RNF128 in patient tissues and cancer cell lines. In patient samples, RNF128 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF128 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and STOMACH.
